Centogene announces publication establishing Lyso-Gb1 as a predictive biomarker for Gaucher disease patients

Centogene Biodatabank reveals unique genetic variants in world’s largest Niemann-Pick Type C1 disease cohort

A project co-funded by Corus finds a new therapeutic alternative for HER2+ breast cancer

Centogene launches new CentoGenome®, world’s most comprehensive whole genome sequencing solution for diagnosis of rare and neurodegenerative diseases

Corus’ presence at the Dental Tribune’s IDS 2023

Centogene is partnering with IQVIA to improve health outcomes for rare disease patients

Corus expands into the UK with the integration of Byrnes Dental Laboratory

Corus grows in Spain with the acquisition of two laboratories in Seville and Madrid

Centogene reaches 12,500 patient milestone in world’s largest observational study on Parkinson’s disease genetics